Cadila Pharmaceuticals human insulin
Insulin human biosimilar developed by Cadila Pharmaceuticals. Reference product Humulin (Lilly); Actrapid, Insulatard and Mixtard (Novo Nordisk); Insuman (Sanofi).
About Cadila Pharmaceuticals human insulin
Cadila Pharmaceuticals received its human insulin permission in India in November 2024, for the premixed form, adding to its filgrastim.
Status by market
United States
Not listed by FDA.
European Union
Not listed by EMA.
United Kingdom
Not listed by MHRA.
Japan
Not listed by PMDA.
Canada
Not listed by HC.
India
Central Drugs Standard Control OrganisationApprovedUnited Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Cadila Pharmaceuticals human insulin holds an approval, these are the other insulin human biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| CDSCO | 8 | Biocon Biologics (Biocon human insulin), Epygen Biotech (Epygen human insulin), Eris Lifesciences (Eris human insulin), Gland Pharma (Gland Pharma human insulin), M.J. Biopharm (M.J. Biopharm human insulin), Not stated in the CDSCO list (Lupin human insulin), Regenix (Regenix human insulin), Sanofi (Shantha human insulin) |
Same developer, other molecules
Other biosimilars in the Atlas developed by Cadila Pharmaceuticals: Cadila Pharmaceuticals filgrastim.
Chronology
- CDSCONov 2024CDSCO permission granted
Sources
Planning insulin human biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant